Citation only
via OpenAlex
Mesenchymal stromal cell senescence in multiple myeloma: what came first?
J Ilic, Bianca Schlierf, Maximilian Rudert, Regina Ebert, Drenka I. Trivanović, Marietta Herrmann
Osteologie/Osteology · 2022
Abstract
Introduction Mesenchymal stromal cells (MSCs) strongly regulate the outgrowth of malignant plasma cells – multiple myeloma (MM) cells. MM, as well as aging, is linked to MSCs’ senescence(definition), influencing their functionality and role in cancer progression. Material and Methods MSCs are isolated from bone marrow of patients undergoing hip arthroplasty. Their viability and proliferation are examined upon treatments with senolytics(definition) quercetin and dasatinib, cytostatic bortezomib and co-cultures with MM cells upon 72 h, via MTT assay and flow cytometry. Metabolic status and senescence specific markers are analyzed with cellular assays and histochemical staining. Results Quercetin and dasatinib decreased the metabolic activity of MSCs significantly, without an effect on their cell cycle. Addition of bortezomib did not influence the senolytic-reduced MSCs growth upon 72 h of treatment. However, when co-cultured with MM cells and treated with bortezomib, MSCs show a decrease in the expression of Ki67, not detectable when only bortezomib is applied. In addition, in co-culture with senescent MSCs, presence of MM cells and bortezomib significantly increased the percentage of β-galactosidase activity in MSCs. Conclusion Our results imply an inhibitory effect MM cells bring to MSC proliferation, particularly when treated with bortezomib, indicating their role in causing a pro-inflammatory senescent phenotype of MSCs. Here, we revealed that the initial replicative state of MSCs is patient-specific, highly variable and dictates their response, which our further research aims to unveil in more detail. Publication History Article published online: 18 October 2022 © 2022. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1055/s-0042-1757527
- Canonical
- link ↗
- Fetched
- 2026-10-09 MST
Cite this
APA
Ilic, J., Schlierf, B., Rudert, M., Ebert, R., Trivanović, D.I., & Herrmann, M. (2022). Mesenchymal stromal cell senescence in multiple myeloma: what came first?. <em>Osteologie/Osteology</em>. https://doi.org/10.1055/s-0042-1757527
Vancouver
Ilic J, Schlierf B, Rudert M, Ebert R, Trivanović DI, Herrmann M. Mesenchymal stromal cell senescence in multiple myeloma: what came first?. Osteologie/Osteology. 2022. doi:10.1055/s-0042-1757527.
BibTeX
@article{j2022Mesenc,
title = {Mesenchymal stromal cell senescence in multiple myeloma: what came first?},
author = {J Ilic and Bianca Schlierf and Maximilian Rudert and Regina Ebert and Drenka I. Trivanović and Marietta Herrmann},
journal = {Osteologie/Osteology},
year = {2022},
doi = {10.1055/s-0042-1757527},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Gut 2011
Citation only
Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease
Blood 2006
Open access · OA
Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting
Aging Cell 2023
Open access · CC-BY
Rutin is a potent senomorphic agent to target senescent cells and can improve chemotherapeutic efficacy
Tissue Engineering Part C Methods 2022
Preprint · OA
Characterization of Induction and Targeting of Senescent Mesenchymal Stromal Cells
International Journal of Molecular Sciences 2013
Open access · CC-BY
Comparative Analysis of Human Mesenchymal Stem Cells from Bone Marrow, Adipose Tissue, and Umbilical Cord Blood as Sources of Cell Therapy
International Journal of Molecular Sciences 2023
Open access · CC-BY